Hanmi Pharm Set to Produce DNA-based COVID-19 Vaccine Developed by Zydus Cadila
Hanmi Pharmaceutical announced that it would begin the production of ZyCoV-D, the COVID-19 plasmid DNA vaccine, developed by Indian pharmaceutical company Zydus Cadila (Zydus).
Hanmi Pharm Bio Plant in Pyeongtaek where Hanmi Pharm and Enzychem Life Sciences will jointly research and produce the DNA-based COVID-19 vaccine from Zydus Cadila (Courtesy of Hanmi Pharm)
To this end, Hanmi Pharm signed a contract for the technology transfer and facility preparation for consignment manufacturing of the ZyCoV-D vaccine with Enzychem Life Sciences on January 7. Enzychem signed a technology transfer agreement with Zydus last year. Hanmi Pharm and Enzychem have begun the optimization process for technology transfer and production facilities to manufacture the drug substance at Hanmi Pharm Bio Plant in Pyeongtaek.
The two companies, which signed a licensing agreement with Zydus last year, has begun the technology transfer and the optimization of the production facilities for the production of the drug substance at Hanmi Pharm Bio Plant in Pyeongtaek.
Hanmi Pharm and Enzychem Life Sciences are expected to sign an additional agreement for mass production of ZyCoV-D in the second quarter this year, which is when the preparation is set to be completed. The maximum production volume aimed by the two companies is about 80 million doses per year.
Meanwhile, ZyCoV-D is a COVID-19 plasmid DNA vaccine that was approved for emergency use by the Drugs Controller General of India (DCGI) last August. The vaccine can be stored at between 2 to 8°C (general temperature for a refrigerator). It can also be stored at about 25°C for up to 3 months, which makes it easy for maintaining a global supply chain.